Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(9%)
Results Posted
120%(6 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_3
2
18%
Ph phase_1
1
9%
Ph phase_4
2
18%
Ph phase_2
4
36%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Not yet recruiting2
Terminated2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 32 (22.2%)
Phase 42 (22.2%)

Trials by Status

not_yet_recruiting218%
unknown19%
completed545%
recruiting19%
terminated218%

Recent Activity

1 active trials
Showing 5 of 11
not_yet_recruitingphase_2

Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection

NCT07555431
recruitingphase_1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255
completed

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
not_yet_recruitingphase_4

Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.

NCT06787976
completed

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

NCT04019873
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07555431Phase 2

Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection

Not Yet Recruiting
NCT02140255Phase 1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Recruiting
NCT04518228

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Completed
NCT06787976Phase 4

Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.

Not Yet Recruiting
NCT04019873

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Completed
NCT04272242Phase 2

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Terminated
NCT02831764Phase 3

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Completed
NCT02831673Phase 3

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Completed
NCT02519777Phase 4

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

Completed
NCT03539224Phase 2

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

Unknown
NCT02386098Phase 2

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11